These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 23474740

  • 21. Therapeutic potentials of aspirin in glaucomatous optic neuropathy.
    Attarzadeh A, Hosseini H, Nowroozizadeh S.
    Med Hypotheses; 2006; 67(2):375-7. PubMed ID: 16527427
    [Abstract] [Full Text] [Related]

  • 22. Ophthalmic drug discovery.
    Clark AF, Yorio T.
    Nat Rev Drug Discov; 2003 Jun; 2(6):448-59. PubMed ID: 12776220
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.
    Löhle M, Reichmann H.
    J Neurol Sci; 2010 Feb 15; 289(1-2):104-14. PubMed ID: 19772974
    [Abstract] [Full Text] [Related]

  • 25. Molecular and cell-based approaches for neuroprotection in glaucoma.
    Lebrun-Julien F, Di Polo A.
    Optom Vis Sci; 2008 Jun 15; 85(6):417-24. PubMed ID: 18521011
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Designing neuroprotection trials in Parkinson's disease.
    Kieburtz K.
    Ann Neurol; 2003 Jun 15; 53 Suppl 3():S100-7; discussion S107-9. PubMed ID: 12666102
    [Abstract] [Full Text] [Related]

  • 30. Rodent models for glaucoma retinopathy and optic neuropathy.
    Pang IH, Clark AF.
    J Glaucoma; 2007 Aug 15; 16(5):483-505. PubMed ID: 17700292
    [Abstract] [Full Text] [Related]

  • 31. Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection.
    Nucci C, Bari M, Spanò A, Corasaniti M, Bagetta G, Maccarrone M, Morrone LA.
    Prog Brain Res; 2008 Aug 15; 173():451-64. PubMed ID: 18929127
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Neuroprotection with carotenoids in glaucoma].
    Neacşu A, Oprean C, Curea M, Tuchilă G, Trifu M.
    Oftalmologia; 2003 Aug 15; 59(4):70-5. PubMed ID: 15083692
    [Abstract] [Full Text] [Related]

  • 34. [Retinal ganglion cells death in glaucoma--mechanism and potential treatment. Part I].
    Rokicki W, Dorecka M, Romaniuk W.
    Klin Oczna; 2007 Aug 15; 109(7-9):349-52. PubMed ID: 18260296
    [Abstract] [Full Text] [Related]

  • 35. Neuroprotection and regeneration in glaucoma.
    Levin LA.
    Ophthalmol Clin North Am; 2005 Dec 15; 18(4):585-96, vii. PubMed ID: 16314221
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Prospects in the medical treatment of glaucomatous neuropathy. Basics of neuroprotection].
    Detry-Morel M.
    J Fr Ophtalmol; 1999 Feb 15; 22(1):122-34. PubMed ID: 10221206
    [No Abstract] [Full Text] [Related]

  • 38. Preventing vision loss from glaucoma: putting data from clinical trials into practice.
    Schoenleber DB.
    Mo Med; 2005 Feb 15; 102(1):51-4. PubMed ID: 15754618
    [Abstract] [Full Text] [Related]

  • 39. Neuroprotection in Parkinson's disease: clinical trials.
    Stocchi F, Olanow CW.
    Ann Neurol; 2003 Feb 15; 53 Suppl 3():S87-97; discussion S97-9. PubMed ID: 12666101
    [Abstract] [Full Text] [Related]

  • 40. Trials of neuroprotective therapies for Parkinson's disease: problems and limitations.
    de la Fuente-Fernández R, Schulzer M, Mak E, Sossi V.
    Parkinsonism Relat Disord; 2010 Jul 15; 16(6):365-9. PubMed ID: 20471298
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.